Menu Toggle menu

AEterna Zentaris Inc.Hires Philip A. Theodore As Chief Management Executive


Boston, MA 10/08/2014  – AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), which is a specialty biopharmaceutical company, announced the election of Philip A. Theodore as its Senior Vice President and Chief Administrative Secretary. He will also act the company’s General Counsel, as well as corporate Secretary. According to the company’s press release, he will be engaged with managing several functions, including corporate development, human resources, legal as well as administrative operations.

Theodore’s Experiences

Before associating with AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), Theodore was playing the role of Vice President at Zep, Inc. (NYSE:ZEP), which is a leading chemical packaged products’ company. At the previous company, he was also enjoying the roles of the General Counsel and Corporate Secretary. Before his tenure at Zep, he worked with BioReliance Corporation for a period of almost one year between Sept 2008 and April 2009. He was employed at BioReliance in the capacity of a VP of its Corporate Development, Compliance and Legal. From Sept 2006 to Sept 2007, he was the Senior VP and General Counsel at John H. Ahrland Company. Prior to that, from 2004 to Aug 2006, he was the VP, General Secretary and Corporate Secretary at Serologicals Corporation. Apart from this, Theodore had been a partner in the corporate practice of an Atlanta-based law firm, King & Spalding, LLP. He served at the firm for a long period spanning from 1986 to 2003.

Theodore has graduated from the University of Cincinnati College of Law. He gained the B.A. degree in Political Science from Chattanooga’s University of Tennessee. On the occasion of joining the new company, he said that he finds it an exciting opportunity to join AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) during its transition phase. The company is transiting into an operating specialty biopharmaceutical company that develops and commercializes new treatments in endocrinology and oncology. Theodore said that the company is on the right track to becoming a commercial-focused entity and he seeks to pay his contribution in its becoming a sustainable, successful and competitive organization.